 |
 |
| Dates | 26 February (Fri.), 27 February (Sat.), 2010 | Chairs | Masakazu Toi (Chief) (President, OOTR) Louis Chow (Executive Director, OOTR) Nadir Arber |
| Theme | Oncological Biomarkers and Clinical Applications | ||
| Venue | The Westin Miyako Hotel Kyoto | ||
| Sponsorships | Kyoto Prefecture, Kyoto City, The Kyoto Shimbun Co.,Ltd, Ministry of Education, Culture, Sports, Science and Technology 'Raising Proficient Oncologists' (Kyoto University) |
||
| The main topics will be - Prognosis and Predictive factors for therapeutic gain / Biomarkers for therapy personalisation. (Antiangiogenesis therapy, Modulation of intracellular signals etc.) |
|||
- Top
- Award-winning posters
- Photo Album
- Welcome Message
- Conference Information
- Invited Specialists
- Programme
- Registration
- Important Dates
- Venue
- Accommodations
- Kyoto Guide
- Day Nursery
- Conference Secretariat
Invited Specialists
(in alphabetical order)
| AAPRO | Matti | Multidisciplinary Oncology Institute, Genolier (Switzerland) |
|---|---|---|
| ARBER | Nadir | Tel Aviv University (Israel) 'Biomarker application in colorectal cancer diagnosis and treatment' |
| BERTOLINI | Francesco | European Institute of Oncology (Italy) 'Circulating endothelial cells as biomarkers in medical oncology' |
| CAO | Yihai | Karolinska Institute (Sweden) 'Local and systemic impacts of antiangiogenic drugs on cancer patients' |
| CHOW | Louis W C | The University of Hong Kong (Hong Kong) |
| GASPARINI | Giampietro | San Filippo Neri Hospital (Italy) 'Predictive factors in rectal and colon cancer: Toward personalised therapy' |
| GUAN | Xin-yuan | The University of Hong Kong (Hong Kong) 'Identification and characterisation of tumor suppressor genes on 3p in esophageal squamous cell carcinoma' |
| INAMOTO | Takashi | Kitano Hospital (Japan) |
| IWATA | Hiroji | Aichi Cancer Centre Hospital (Japan) |
| KAKEYA | Hideaki | Kyoto University (Japan) |
| KANAI | Masashi | Kyoto University (Japan) 'Pharmacogenetic approach to predict clinical response of chemotherapy in advanced colorectal cancer patients' |
| KERBEL | Robert S | Sunnybrook Research Institute (Canada) 'Metronomic chemotherapy: Recent preclinical and clinical advances' |
| KROP | Ian E | Dana-Farber Cancer Institute (USA) 'Novel strategies to overcome trastuzumab resistance in HER2 positive breast cancer' |
| KUMAR | Rakesh | The George Washington University Medical Centre (USA) 'PAK1-driven oncologic pathways' |
| KUROI | Katsumasa | Tokyo Metropolitan Cancer and Infectious Diseases Centre Komagome Hospital (Japan) |
| LU | Janice | State University of New York (USA) 'Circulating tumor cells for individualised cancer treatment' |
| MANO | Hiroyuki | Jichi Medical University/University of Tokyo (Japan) 'Discovery and clinical application of a lung cancer oncogene, EML4-ALK' |
| NAKAMURA | Seigo | St. Luke's International Hospital Breast Centre (Japan) |
| OHNO | Shinji | National Kyushu Cancer Centre (Japan) |
| RUGO | Hope S | University of California San Francisco (USA) 'Molecularly targeted therapy for breast cancer' |
| SABE | Hisataka | Hokkaido University (Japan) 'Integrin activation and E-cadherin inactivation by the Arf6 pathway specific to breast cancer invasion and metastasis' |
| SASANO | Hironobu | Tohoku University (Japan) 'Vaschibin-1 in human breast carcinoma: A potential negative feedback regulator of angiogenesis and a marker for neovascularisation' |
| SAYA | Hideyuki | Keio University (Japan) 'Significance of epithelial mesenchymal transition (EMT) in cancer malignancy' |
| SCHERER | Stefan J | F. Hoffmann-La Roche / Genentech (USA) 'Molecular biomarkers for bevacizumab' |
| SMINIA | Peter | VU University Medical Centre (Holland) 'MGMT status of human glioma cells and response to temozolomide, irradiation and nelfinavir' |
| TOI | Masakazu | Kyoto University (Japan) |
| UENO | Takayuki | Kyoto University (Japan) |
| UMEZAWA | Kazuo | Keio University (Japan) 'Apoptosis and its regulation by chemical ligands' |
| WINER | Eric P | Harvard University (USA) 'The role of angiogenesis inhibitors in the treatment of breast cancer' |
* The above is subjected to change.